GLUEMonte Rosa Therapeutics, Inc.
$10.83+5.0% 1Y
$10.83
$9.3552 weeks$25.31
Is the price fair?
What GLUE's price assumes
Monte Rosa Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 32.2× revenue.
32.2
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.90
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 27.6
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.90
- EV / EBIToperating margin −633%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 27.6
- Market capitalisation85.3 million shares, counted Jul 31, 2026
- $924M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks